restor3D raised USD $4.4 million in equity, bringing its total raised to $5.4 million since 2017. The company develops 3D-printed implants, and entered into a development and licensing agreement with SeaSpine in late 2019.
restor3d’s materials science technology complements SeaSpine's orthobiologics portfolio. They will leverage their specialties to develop interbodies for a range of surgical approaches, while driving clinical and economic advantages.
Products arising from this collaboration are slated for launch in 2H20.